» Articles » PMID: 33074422

"Cerebral Small Vessel Disease and Other Influential Factors of Cognitive Impairment in the Middle-aged: a Long-term Observational Cohort PURE-MIND Study in Poland"

Overview
Journal Geroscience
Specialty Geriatrics
Date 2020 Oct 19
PMID 33074422
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

A complex picture of factors influencing cognition is necessary to be drawn for a better understanding of the role of potentially modifiable factors in dementia. The aim was to assess the prevalence and determinants of cognitive impairment, including the role of cerebral small vessel disease (CSVD) in Polish middle-aged cohort. A comprehensive set of clinical (hypertension, coronary heart disease, diabetes mellitus, hyperlipidaemia, body mass index, smoking status, alcohol intake) and socio-demographic data was collected in the PURE study in years 2007-2016, which was the basis for detailed analysis of risk factors of cognitive impairments in years 2016-2018 in the PURE-MIND sub-study. Five hundred forty-seven subjects (age range 39-65, mean 56.2 ± 6.5) underwent neuropsychological assessment with Montreal Cognitive Assessment (MoCA), Trail Making Test (TMT) and Digit Symbol Substitution Test (DSST) followed by brain MRI. Mean MoCA score was 26.29 and 33% participants met criteria for mild cognitive impairment (MCI) (MoCA< 26). Seventy-three percent showed findings related to CSVD. Higher WMH burden and lacunar infarcts were associated with lower MoCA and DSST scores. Severe CSVD was associated with twofold incidence of MCI, and obesity increased its probability by 53% and hypertension by 37%. The likelihood of MCI was reduced in nonsmokers. One factor analysis showed the important role of lower level of education, older age, rural area of residence and hypertension. MCI and CSVD are highly prevalent in the middle-aged population in Poland. A greater importance should be given to potentially modifiable risk factors of dementia which are already present in mid-life.

Citing Articles

Prediction models for cognitive impairment in middle-aged patients with cerebral small vessel disease.

Zheng W, Qin X, Mu R, Yang P, Huang B, Song Z Front Neurol. 2025; 16:1462636.

PMID: 40007740 PMC: 11850248. DOI: 10.3389/fneur.2025.1462636.


Potential biomarkers for cerebral small vessel disease with cognitive impairment: a systematic review and meta-analysis.

Liao L, Huang W, Ma R, He X, Su M, Sha D Front Aging Neurosci. 2025; 16():1475571.

PMID: 39839309 PMC: 11747022. DOI: 10.3389/fnagi.2024.1475571.


Additive effects of cerebrovascular disease functional connectome phenotype and plasma p-tau181 on longitudinal neurodegeneration and cognitive outcomes.

Chong J, Ji F, Hilal S, Chong J, Lau J, Tong N Alzheimers Dement. 2024; 20(12):8739-8757.

PMID: 39537356 PMC: 11667494. DOI: 10.1002/alz.14328.


Improving Cognitive Function with Nutritional Supplements in Aging: A Comprehensive Narrative Review of Clinical Studies Investigating the Effects of Vitamins, Minerals, Antioxidants, and Other Dietary Supplements.

Fekete M, Lehoczki A, Tarantini S, Fazekas-Pongor V, Csipo T, Csizmadia Z Nutrients. 2023; 15(24).

PMID: 38140375 PMC: 10746024. DOI: 10.3390/nu15245116.


Midlife hypertension is a risk factor for some, but not all, domains of cognitive decline in later life: a systematic review and meta-analysis.

Joyce O, McHugh C, Mockler D, Wilson F, Kelly A J Hypertens. 2023; 42(2):205-223.

PMID: 37937515 PMC: 10763710. DOI: 10.1097/HJH.0000000000003614.


References
1.
Legdeur N, Heymans M, Comijs H, Huisman M, Maier A, Visser P . Age dependency of risk factors for cognitive decline. BMC Geriatr. 2018; 18(1):187. PMC: 6102935. DOI: 10.1186/s12877-018-0876-2. View

2.
Petersen R . Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia. 2000; 15(3):93-101. View

3.
Anand S, Friedrich M, Desai D, Schulze K, Awadalla P, Busseuil D . Reduced Cognitive Assessment Scores Among Individuals With Magnetic Resonance Imaging-Detected Vascular Brain Injury. Stroke. 2020; 51(4):1158-1165. DOI: 10.1161/STROKEAHA.119.028179. View